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Abstract
Purpose Insulinomas are neuroendocrine tumours derived
from pancreatic β-cells. The glucagon-like peptide 1
receptor (GLP-1R) is expressed with a high incidence
(>90%) and high density in insulinomas. Glucagon-like
peptide 1 (GLP-1), the natural ligand of GLP-1R, is rapidly
degraded in vivo. A more stable agonist of GLP-1R is
exendin-3. We investigated imaging of insulinomas with
DOTA-conjugated exendin-3 labelled with
68Ga.
Methods Targeting of insulinomas with [Lys
40(DOTA)]
exendin-3 labelled with either
111In or
68Ga was investiga-
ted in vitro using insulinoma tumour cells (INS-1).
[Lys
40(
111In-DTPA)]Exendin-3 was used as a reference in
this study. In vivo targeting was investigated in BALB/c
nude mice with subcutaneous INS-1 tumours. PET imaging
was performed using a preclinical PET/CT scanner.
Results In vitro exendin-3 specifically bound and was
internalized by GLP-1R-positive cells. In BALB/c nude
mice with subcutaneous INS-1 tumours a high uptake of
[Lys
40(
111In-DTPA)]exendin-3 in the tumour was observed
(33.5±11.6%ID/g at 4 h after injection). Uptake was
specific, as determined by coinjection of an excess of
unlabelled [Lys
40]exendin-3 (1.8±0.1%ID/g). The pancreas
also exhibited high and specific uptake (11.3±1.0%ID/g).
High uptake was also found in the kidneys (144±24%ID/g)
and this uptake was not receptor-mediated. In this murine
tumour model optimal targeting of the GLP-1R expressing
tumour was obtained at exendin doses ≤0.1 µg. Remark-
ably, tumour uptake of
68Ga-labelled [Lys
40(DOTA)]exen-
din-3 was lower (8.9±3.1%ID/g) than tumour uptake of
111In-labelled [Lys
40(DTPA)]exendin-3 (25.4±7.2%ID/g).
The subcutaneous tumours were clearly visualized by
small-animal PET imaging after injection of 3 MBq of
[Lys
40(
68Ga-DOTA)]exendin-3.
Conclusion [Lys
40(
68Ga-DOTA)]Exendin-3 specifically
accumulates in insulinomas, although the uptake is lower
than that of [Lys
40(
111In-DTPA)]exendin-3. Therefore,
[Lys
40(
68Ga-DOTA)]exendin-3 is a promising tracer to
visualize insulinomas with PET.
Keywords Insulinoma.GLP-1receptor.Imaging.SPECT.
PET.Exendin
Introduction
Insulinomas are neuroendocrine tumours (NET) derived
from pancreatic beta-cells. The diagnosis is based on
clinical symptoms (such as neuroglycopenic symptoms)
and biochemical parameters (endogenous hyperinsulinism
confirmed by hypoglycaemia). The standard treatment for
insulinomas is surgical resection, requiring exact localiza-
tion of the tumour lesions. Therefore, patients usually
undergo computed tomography (CT) and magnetic reso-
nance imaging (MRI) to precisely localize the primary
tumour and potential metastases in those with malignant
insulinoma. Somatostatin receptor scintigraphy (SRS) is
considered the most sensitive method for detection of NET
[1]. In contrast to other NET, the sensitivity of SRS for
detecting insulinomas is only 40–60% due to the relatively
low incidence of somatostatin subtype receptor (sstr) 2 and
sstr5 expression in insulinomas [1–3]. Therefore, SRS is
not suitable for localizing insulinomas. Recent studies have
shown a high detection rate of insulinomas with endoscopic
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DOI 10.1007/s00259-009-1363-yultrasonography [4]. However, the high detection rate is
limited to tumours that are located in the head and the body
of the pancreas. Moreover, this technique requires special-
ized expertise and is observer-dependent. Angiography
shows reasonable localization of insulinomas in approxi-
mately 70% of patients. However, the localization varies
from 43% to 94% due to observer-dependency [5]. Arterial
stimulation and venous sampling is a sensitive method that
is able to localize over 90% of insulinomas [5]. The major
drawback is that the procedure is invasive. Thus, there is a
need for new noninvasive strategies for localization of
insulinomas.
The glucagon-like peptide 1 receptor (GLP-1R) is
expressed in >90% of insulinomas at a mean density twice
thatofsstr2[6]. First preclinical studies have shown that
123I-
GLP-1 and
123I-exendin-3 accumulate in rat insulinomas
(RINm5F) subcutaneously implanted in NEDH rats, and that
these tumours can be detected scintigraphically [7]. How-
ever, radioiodinated peptides have a relatively low uptake in
vivo, due to washout of the radionuclide after internalization
[8–11]. Recent studies have shown high uptake of DTPA-
conjugated [Lys
40]exendin-4 labelled with
111In in the
Rip1Tag2 spontaneous insulinoma mouse model [12, 13].
Moreover, administration of a therapeutic dose of
111In-
labelled [Lys
40(DTPA)]exendin-4 markedly inhibited the
growth of insulinomas in Rip1Tag2 mice [14]. Based on
these promising results,
111In-labelled exendin-4 has been
used for the detection of insulinomas in humans by single
photon emission computed tomography (SPECT) [15].
Previous studies have used exendin-3 and exendin-4, which
share 95% homology (Table 1). Exendin-3 and exendin-4
differ in two amino acids (positions 2 and 3) located in the
region of the peptide that is involved in internalization of the
receptor–ligand complex, which might lead to differences in
biodistribution of these peptides. In this study we therefore
compared the biodistribution of [Lys
40(DTPA)]exendin-3
and [Lys
40(DTPA)]exendin-4 labelled with
111In.
Because even small insulinomas may induce clinical
symptoms, imaging methods for the detection of these
tumours needs to be highly sensitive. Positron emission
tomography (PET) may therefore offer an advantage over
SPECT because of its excellent sensitivity in combination
with its improved spatial resolution. As the radionuclide for
PET imaging of GLP-1Rs with exendin,
68Ga seems to be
the optimal candidate since DOTA-conjugated probes can
be rapidly and efficiently labelled with
68Ga, and because
68Ga is a generator-produced positron emitter, it is widely
available and relatively cheap. The conjugation of exendin-
3 with DOTA could change the pharmacokinetics of the
peptide. Therefore we compared the biodistribution of
[Lys
40(DTPA)]exendin-3 and [Lys
40(DOTA)]exendin-3
labelled with
111In.
We determined the potential of
68Ga-labelled [Lys
40
(DOTA)]exendin-3 for insulinoma imaging. [Lys
40(
111In-
DTPA)]exendin-4 was successfully used for this application
[12, 14, 15]. Here, biodistributions of [Lys
40(
111In-DTPA)]
exendin-3 and [Lys
40(
111In-DTPA)]exendin-4 were com-
pared. The effect of the chelator (DOTA or DTPA) was
examined by comparing the biodistributions of [Lys
40
(
111In-DTPA)]exendin-3 and [Lys
40(
111In-DOTA)]exendin-
3. The biodistributions of
68Ga- and
111In-labelled exendin-
3 were compared. Finally, microPET images were acquired
of insulinoma-bearing BALB/c nude mice after injection of
[Lys
40(
68Ga-DOTA)]exendin-3.
Materials and methods
Peptides and radionuclides
[Lys
40(DOTA)]exendin-3, [Lys
40(DTPA)]exendin-3 and
[Lys
40(DTPA)]exendin-4 were purchased from Peptide Spe-
cialty Laboratories (Heidelberg, Germany). The DTPA or
DOTA was conjugated to the ε-amino group of the lysine
(K40) and the C-terminal carboxyl group was amidated. The
structures of [Lys
40(DTPA)]exendin and Lys
40(DOTA)]exen-
din are shown in Fig. 1.
111InCl3 was obtained from
Covidien (Petten, The Netherlands).
68GaCl3 was eluted
from a TiO2-based 1,110 MBq
68Ge/
68Ga generator
(Obninsk, Russia) with 0.1 N Ultrapure HCl (J.T. Baker,
Deventer, The Netherlands).
Radiolabelling
[Lys
40(DTPA)]Exendin-3 was dissolved in 0.1 M MES (2-
(N-morpholino)ethanesulphonic acid) buffer, pH 5.5, and
150 MBq
111In was added to 1 µg peptide followed by five
volumes of 0.1 M MES buffer, pH 5.5, resulting in a total
volume of reaction mixture ranging from 800 µl to
2,345 µl. After incubation at room temperature for
30 min, quality control was performed using reversed-phase
high-performance liquid chromatography (RP-HPLC) on a
C18 reversed-phase column (Zorbax Rx-C18; 4.6 mm×
25 cm; Agilent Technologies) and instant thin-layer chroma-
Peptide Amino acid sequence
Exendin-3 HSDGTFTSDLSKQMEEEAVRLFIEWLKNGGPSSGAPPPS-NH2
Exendin-4 HGEGTFTSDLSKQMEEEAVRLFIEWLKNGGPSSGAPPPS-NH2
Table 1 Amino acid structures
of exendin-3 and exendin-4.
Homologous amino acids are
underlined
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ammonium acetate, pH 5.5, with a linear gradient from 3%
to 100% acetonitrile in 10 min (flow rate 1 ml/min). ITLC
was performed on silica gel ITLC (Pall Corporation Life
Sciences, New York, NY). Two mobile phases were used:
0.1 M EDTA in 0.1 M NH4Ac, pH 5.5 (Rf
111In-labelled
exendin = 0, Rf unbound
111In = 1) and 0.25 M NH4Ac (pH
5.5)/methanol (1:1) (Rf colloidal residues = 0: , Rf
111In-
labelled exendin and unbound
111In = 1).
[Lys
40(DOTA)]Exendin-3 was labelled with
111In by
adding five volumes of 0.25 M ammonium acetate buffer,
pH 5.5, containing 5 µg peptide and 55 MBq
111In,
resulting in a total volume of reaction mixture ranging
from 359 µl to 1,043 µl. After 20 min incubation at 95°C,
quality control was performed using RP-HPLC and ITLC
as described above. [Lys
40(DOTA)]exendin-3 was labelled
with
68Ga by adding 185 MBq of
68Ga in 350 µl 0.1 N
Ultrapure HCl to 42 µl 2.5 M HEPES (4-(2-hydroxyethyl)-
1-piperazineethanesulphonic acid) buffer, pH 7, containing
8µ g[ L y s
40(DOTA)]exendin-3. The final pH of the reaction
mixture was 3.0. The mixture was incubated at 95°C for
15 min, then EDTA was added to a final concentration of
5m M, and the mixture was incubated at room temperature
for 5 min. The reaction mixture was purified by HPLC
using a C8 reversed-phase column (Zorbax eclipse XDB C8
4.6×150 mm, 5 µm; Agilent Technologies). The column
was eluted with 10 mM ammonium acetate, pH 5.5 (0–
5 min) and 40% ethanol (5–10 min) followed by a linear
gradient from 40% to 90% ethanol over 5 min (flow rate
1 ml/min). The fractions containing [Lys
40(
68Ga-DOTA)]
exendin-3 were collected and diluted with PBS containing
0.5% BSA to a final ethanol concentration of less than 10%
before injection into mice (injection volume 0.2 ml). The
contents of unincorporated
68Ga and
68Ga colloid in the
purified
68Ga-labelled [Lys40(DOTA)]exendin-3 prepara-
tions were determined using ITLC as described above.
Cell culture
The rat insulinoma cell line INS-1 [16] was maintained in
RPMI-1640 medium supplemented with 10% fetal bovine
serum, 2 mM glutamine, 10 mM HEPES, 50 µM β-
mercaptoethanol, 1 mM sodium pyruvate, 100 U/ml
penicillin and 100 µg/ml streptomycin, in a humidified
atmosphere containing 5% CO2 at 37°C. The cells were
harvested by trypsinization with trypsin/EDTA.
IC50 determination
The 50% inhibitory concentrations (IC50)o f[ L y s
40(
natIn-
DTPA)]exendin-3, [Lys
40(
natIn-DOTA)]exendin-3 and
[Lys
40(
natGa-DOTA)]exendin-3 were determined using sus-
pensions of INS-1 cells. [Lys
40(DTPA)]Exendin-3 was
labelled with stable
natIn by adding 10.6 nmol
natInCl3
(Merck, Darmstadt, Germany) to 2.12 nmol [Lys
40(DTPA)]
exendin-3 (0.21 nmol/µl) in 30 µl 0.1 M MES buffer, pH
5.5, and incubated at room temperature for 30 min.
[Lys
40(DOTA)]Exendin-3 was labelled with
natIn in 0.25 M
NH4Ac, pH 5.5, containing 2.12 nmol [Lys
40(DOTA)]
exendin-3. After adding 10.6 nmol
natIn, the reaction mixture
was incubated at 95°C for 30 min. [Lys
40(DOTA)]exendin-3
was labelled with stable
natGa by adding 10.6 nmol
natGa
(NO)3 (Sigma Aldrich, St Louis, MO) to 2.12 nmol
[Lys
40(DOTA)]exendin-3 in 30 µl 0.25 M NH4Ac, pH 5.5,
followed by incubation at room temperature for 3 h. INS-1
cells were resuspended in binding buffer (HEPES-buffered
RPMI containing 1% BSA) to a concentration of 3 million
cells/0.5 ml. After 10 min incubation at 0°C,
natIn- or
natGa-
labelled peptide was added to a final concentration in the
range 0.10–350 nM along with radiolabelled [Lys
40(
111In-
DTPA)]exendin-3 (60,000 dpm). To prevent internalization,
cells were incubated on ice for 4 h. The cell suspension was
centrifuged at 3,000 g for 5 min and the supernatant was
discarded. The cells were washed twice with ice-cold PBS,
centrifuged, and the radioactivity in the cell pellet was
determined in a gamma-counter (Wizard, Wallac-Oy,
Uppsala, Sweden), and the bound fraction was determined.
In vitro internalization
The kinetics of internalization of [Lys
40(
111In-DTPA)]
exendin-3 were determined as described previously [17].
Fig. 1 Structures of
[Lys
40(DTPA)]exendin-3 (a) and
[Lys
40(DOTA)]exendin-3 (b)
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in six-well plates and incubated overnight at 37°C. The
cells were washed twice with binding buffer and subse-
quently incubated at 37°C for 10 min in 1.0 ml binding
buffer. Approximately 60,000 dpm of
111In-labelled peptide
(55 fmol) was added followed by incubation for 0.5, 1, 2 or
4 h at 37 C. To determine nonspecific binding, 1 µg
unlabelled [Lys
40]exendin-3 was added together with the
111In-labelled peptide to three wells per time point. After
incubation, the cells were washed twice with binding
buffer. To determine the surface-bound radiolabelled pep-
tide, ice-cold acid buffer (0.1 M acetic acid, 154 mM NaCl,
pH 2.5) was added and cells were incubated for 10 min at
4°C. After washing the cells twice with binding buffer, they
were harvested with a cotton stick and the cell-associated
activity was measured in a gamma-counter. The internalized
fraction (cell-associated activity after acid wash) and the
receptor-bound fraction (activity removed by acid wash)
were determined. The values of the internalized and
receptor bound fractions were corrected for nonspecific
binding as determined by coincubation with an excess of
unlabelled [Lys
40]exendin-3 (1 µg/well).
Biodistribution studies of [Lys
40(
111In-DTPA)]exendin-3
and [Lys
40(
111In-DTPA)]exendin-4
The biodistributions of [Lys
40(
111In-DTPA)]exendin-3 and
[Lys
40(
111In-DTPA)]exendin-4 were compared. Female
BALB/c nude mice at 6–8 weeks of age were injected
subcutaneously in the right flank with 0.2 ml of a
suspension of INS-1 cells containing 5×10
7 cells/ml. When
the tumours were 2–5 mm in diameter, the mice were
randomly divided into groups of five mice each. The mice
were injected intravenously with 370 kBq (peptide dose
0.1 µg) of
111In-labelled [Lys
40(DTPA)]exendin-3 (n=5) or
111In-labelled [Lys
40(DTPA)]exendin-4 (n=5) via the tail
vein. The mice were killed 4 h after injection by CO2/O2
suffocation, and blood, tumour and relevant tissues (mus-
cle, heart, lung, spleen, pancreas, kidney, liver, stomach and
duodenum) were removed, weighed and counted in a
gamma-counter. The percentage injected dose per gram
(%ID/g) was determined for each tissue. To determine
whether the exendin uptake is GLP-1R-mediated, a 100-
fold excess (10 μg) of unlabelled [Lys
40]exendin was
coinjected in a separate group of two mice.
Biodistribution studies of [Lys
40(
111In-DTPA)]exendin-3
and [Lys
40(
111In-DOTA)]exendin-3
In order to determine the effect of the chelator, the biodis-
tributions of [Lys
40(
111In-DTPA)]exendin-3 and [Lys
40(
111In-
DOTA)]exendin-3 were determined in BALB/c nude mice
with a subcutaneous tumour. The mice were injected
intravenously with 370 kBq
111In-labelled [Lys
40(DTPA)]
exendin-3 (n= 5 )o r[ L y s
40(DOTA)]exendin-3 (n=5). To
determine the GLP-1R-mediated uptake, a separate group of
two mice were coinjected with an excess of unlabelled
[Lys
40]exendin. The mice were killed 4 h after injection by
CO2 suffocation, and blood, tumour and major organs were
removed, weighed and counted.
Biodistribution studies of [Lys
40(
111In-DTPA)]exendin-3
and [Lys
40(
68Ga-DOTA)]exendin-3
The biodistributions of [Lys
40(
111In-DTPA)]exendin-3 and
[Lys
40(
68Ga-DOTA)]exendin-3 were determined in BALB/c
nude mice with subcutaneous INS tumours. Mice were
injected intravenously with 370 kBq
111In (n=5) or 1 MBq
68Ga-labelled exendin-3 (n=5) at a peptide dose of 0.1 µg.
To determine the GLP-1R-mediated uptake, a separate group
of two mice were co-injected with an excess of unlabelled
[Lys
40]exendin. Another group of two mice were injected
with [Lys
40(
68Ga-DOTA)]exendin-3 that was purified on a
disposable PD10 column instead of by RP-HPLC. The mice
were killed 1 h after injection by CO2 suffocation, and blood,
tumour and major organs were removed, weighed and
counted.
Peptide dose-escalation study
To determine the optimal peptide dose of exendin-3 in this
model for tumour imaging, BALB/c nude mice with a
subcutaneous INS-1 tumour were injected intravenously
with 370 kBq [Lys
40(
111In-DTPA)]exendin-3 (peptide dose
0.003 µg) and were coinjected with various amounts of
unlabelled [Lys
40]exendin-3 to final peptide doses in the
range 0.003–10.0 µg (five mice per peptide dose). The mice
were killed 4 h after injection by CO2/O2 suffocation, and
the radioactivity in the blood, tumour and relevant tissues
was measured in a gamma counter.
PET imaging
PET images were acquired of BALB/c nude mice (n=3)
with a subcutaneous INS-1 tumour in the hind limb using a
small-animal PET/CT scanner (Inveon; Siemens Medical
Solutions, Knoxville, TN). The scanner had an axial field of
view of 12.7 cm and a 1.4-mm FWHM spatial resolution in
images reconstructed using Fourier rebinning and filtered
back projection. When the tumours had a diameter of 2–
5 mm, the mice were injected intravenously via the tail vein
with 3 MBq HPLC-purified [Lys
40(
68Ga-DOTA)]exendin-3
(specific activity 110 GBq at completion of the labelling,
50 GBq/µmol at time of injection) corresponding with an
exendin dose of 0.3 µg. PET images were acquired 1 h after
injection under isoflurane/O2/N2O inhalation anaesthesia.
1348 Eur J Nucl Med Mol Imaging (2010) 37:1345–1355The PET images were acquired over 45 min for the
emission scan, and the images were reconstructed by
OSEM3D/MAP reconstruction.
Results
Radiolabelling
Specific activities up to 700 GBq/μmol for [Lys
40(
111In-
DTPA)]exendin-3 were obtained with a radiochemical
purity exceeding 95%. [Lys
40(DOTA)]exendin-3 was la-
belled efficiently with
111In and
68Ga. Specific activities of
20 GBq/µmol with a radiochemical purity >95% as
determined by HPLC were obtained for [Lys
40(
111In-
DOTA)]exendin-3. [Lys
40(DOTA)]exendin-3 was labelled
with
68Ga with a specific activity of 110 GBq/µmol with a
radiochemical purity >99% after HPLC purification. With-
out HPLC purification, a specific activity of 17 GBq/µmol
was obtained. Unbound
111In and
68Ga eluted from the
column after 3 min, whereas
111In- and
68Ga-labelled
exendin had a retention time of about 13 min.
IC50 determination
The results of the IC50 determination are shown in Fig. 2.
The IC50 for
natIn-DTPA-[Lys
40]exendin-3, [Lys
40(
natIn-
DOTA)]exendin-3 and [Lys
40(
natGa-DOTA)]exendin-3 for
binding to INS-1 cells were 8.5 nM (95% confidence
Interval 4.30 to 16.8 nM), 5.3 nM (95% confidence Interval
2.75 to 11.1 nM), and 5.7 nM (95% confidence Interval
2.91 to 11.3 nM), respectively; there was no significant
difference among these IC50 values (p=0.5038 for log(IC50)
differences determined by the F-test).
Internalization kinetics
Figure 3 summarizes the internalization kinetics of [Lys
40
(
111In-DTPA)]exendin-3 in INS-1 cells as determined in
vitro. After 0.5 h, 0.1±0.03 fmol [Lys
40(
111In-DTPA)]
exendin-3 was bound to the receptor and 0.4±0.01 fmol
was internalized. After 4 h these values had increased to
2.6±0.04 and 3.9±0.06 fmol, respectively.
Biodistribution studies of [Lys
40(
111In-DTPA)]exendin-3,
[Lys
40(
111In-DTPA)]exendin-4, and of [Lys
40(
111In-DOTA)]
exendin-3
Figure 4 summarizes the biodistributions of [Lys
40(
111In-
DTPA)]exendin-3 and [Lys
40(
111In-DTPA)]exendin-4. Both
111In-labelled exendin-3 and exendin-4 showed high tumour
uptake (36.0±5.4%ID/g and 36.3±8.0%ID/g). Coadminis-
tration of an excess of unlabelled [Lys
40]exendin-3 blocked
the tumour uptake (1.2±0.3%ID/g and 1.0±0.4%ID/g,
respectively; p<0.01), indicating that the uptake is GLP-1R-
mediated. Specific uptake of [Lys
40(
111In-DTPA)]exendin-3
and [Lys
40(
111In-DTPA)]exendin-4 was also seen in the
pancreas (p<0.01), lung (p<0.01) and stomach (p<0.01),
but there was no significant difference in uptake in tumour,
pancreas, lung or stomach. The renal uptake of [Lys
40(
111In-
DTPA)]exendin-3 and [Lys
40(
111In–DTPA)]exendin-4 was
146.1±21.0%ID/g and 140.5±17.7%ID/g, and this was not
blocked by an excess of unlabelled exendin-3, indicating that
the uptake is not GLP-1R-mediated.
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Fig. 2 Competition binding as-
say (IC50)o f[ L y s
40(
natIn-DTPA)]
exendin-3, [Lys
40(
natIn-DOTA)]
exendin-3 and [Lys
40(
natGa-
DOTA)]exendin-3 in INS-1 cells.
[Lys
40(
111In-DTPA)]exendin-3
was used as tracer
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40]
exendin-3 as evidenced by the almost identical concen-
trations of [Lys
40(
111In-DOTA)]exendin-3 and [Lys
40(
111In-
DTPA)]exendin-3 in all tissues examined (Fig. 5).
Biodistribution of [Lys
40(
68Ga-DOTA)]exendin-3
The biodistribution of [Lys
40(
68Ga-DOTA)]exendin-3
was determined 1 h after injection in BALB/c nude mice
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Fig. 6 Biodistributions of [Lys
40(
111In-DTPA)]exendin-3 and
[Lys
40(
68Ga-DOTA)]exendin-3 in BALB/c nude mice bearing a
subcutaneous INS-1 tumour. Values are mean percentage injected
dose per gram tissue (n=5 mice, error bars SD). Blocking was
performed by coinjection of a 100-fold molar excess of unlabelled
[Lys
40]exendin-3. Mice were dissected 1 h after injection
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40(
111In-
DTPA)]exendin-3 as a reference (Fig. 6). Specific uptake
of [Lys
40(
68Ga-DOTA)]exendin-3 was observed in tumour
(p<0.05) and pancreas (p<0.05). Uptake of [Lys
40(
68Ga-
DOTA)]exendin-3 was significantly lower than that of
[Lys
40(
111In-DTPA)]exendin-3 in tumour (25.4±7.2%ID/g
and 8.9±3.1 ID/g, p<0.01) and pancreas (17.5±2.8%ID/g
and 6.7±1.8%ID/g, p<0.001).
In contrast to the RP-HPLC-purified preparation,
[Lys
40(
68Ga-DOTA)]exendin-3 purified by gel filtration
on a Sephadex G-25 column showed enhanced uptake in
the spleen and liver (16.8±0.9%ID/g and 20.9±1.6%ID/
g, respectively). This enhanced hepatic and splenic
uptake was not receptor-mediated as it could not be
blocked by coinjection of an excess of unlabelled [Lys
40]
exendin (data not shown).Very low uptake in the liver
and spleen was observed when RP-HPLC-purified
[Lys
40(
68Ga-DOTA)]exendin-3 was injected (0.44±
0.05%ID/g and 0.25±0.02%ID/g, respectively). Again,
no specific uptake was observed in the liver and spleen as
determined by coadministration of an excess of unla-
belled exendin (0.31±0.02%ID/g and 0.20±0.01%ID/g,
respectively).
Peptide dose escalation study
Theeffectoftheexendin-3doseonthebiodistributioninmice
with subcutaneous INS-1 tumours was studied in a peptide
doseescalationstudy.Theresultsofthisstudyaresummarized
inFig.7. The highest uptake of [Lys
40(
111In-DTPA)]exendin-
3 was observed when doses ≤0.1 µg of peptide were
administered. Administration of 0.3 µg [Lys
40(DTPA)]
exendin-3 resulted in a significantly reduced uptake of
[Lys
40(
111In-DTPA)]exendin-3 in the tumour and the pancre-
as (p<0.0005 and p=0.001, respectively). Further escalation
of the peptide dose resulted in a further decrease in tumour
and pancreatic uptake of [Lys
40(
111In-DTPA)]exendin-3.
PET imaging
Subcutaneous INS-1 tumours in the hind limb were clearly
visualized on the PET images as early as 1 h after injection
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Fig. 7 Peptide dose escalation study of [Lys
40]exendin-3 in BALB/c
nude mice with a subcutaneous INS-1 tumour. Mice were injected
intravenously with 0.37 MBq [Lys
40(
111In-DTPA)]exendin-3 and were
coinjected with various amounts of unlabelled [Lys
40]exendin 3
ranging from 0.003 to 10.0 µg. Values are mean percentage injected
dose per gram tissue (n=5 mice, error bars SD). Mice were dissected
4 h after injection
1352 Eur J Nucl Med Mol Imaging (2010) 37:1345–1355(Figs. 8 and 9). The PET images were fused with CT
images. As well as high uptake in tumour, uptake was also
seen in the kidneys. PET images following injection with
unpurified [Lys
40(
68Ga-DOTA)]exendin-3 showed high
uptake in the liver (Fig. 8c). Despite the high liver uptake
tumours were still clearly visible.
Discussion
SRS, the standard method for imaging of NET, detects only
around 50% of insulinomas [1, 2, 12]. Clinical studies with
18F-DOPA PET for the detection of insulinomas have
shown promising results [18]. However, physiological
uptake of
18F-DOPA in the pancreas and duodenum may
cause false-positive results or mask small lesions. An
exendin-based imaging method targeting the GLP-1R
specifically expressed on insulinomas might therefore
improve the visualization of insulinomas.
Preclinical studies with [Lys
40(
111In-DTPA)]exendin-4 in
different animal models have shown high accumulation of
111In-labelled exendin in insulinomas [12, 13]. Wild et al.
demonstrated that in vivo imaging of insulinomas by
SPECT with radiolabelled exendin is feasible in patients
[15]. In a transgenic mouse model, they detected insulino-
mas of less than 1 mm in diameter using [Lys
40(
111In-
DTPA)]exendin-4 as tracer. Although SPECT has a higher
resolution in small-animal imaging, for clinical imaging
PET offers a higher spatial resolution, a higher sensitivity
and the possibility to accurately quantify uptake, which
makes it preferable to SPECT. Recent studies have shown
that PET imaging of NET with
68Ga-labelled octreotide is
superior to SPECT imaging with
111In-labelled octreotide
[19, 20].
In this study we therefore investigated the potential of
[Lys
40(
68Ga-DOTA)]exendin-3 for the detection of insuli-
nomas by PET in a mouse model. Conjugation of [Lys
40]
exendin-3 with DOTA instead of DTPA allows radio-
labelling of the tracer with a broad range of radionuclides
including the positron emitter
68Ga. We selected
68Ga as
positron emitter because it is a generator-derived radionu-
clide (and therefore readily available), the labelling strategy
is fast and relatively simple, and the half-life matches the
pharmacokinetics of the tracer (exendin) [13]. A potential
Fig. 8 Maximum intensity projection of PET images of different
BALB/c nude mice with a subcutaneous INS-1 tumour in the right
hind limb. a, b PET images of mice injected with HPLC-purified
[Lys
40(
68Ga-DOTA)]exendin-3. The tumour (arrows) and kidneys are
clearly visible. c PET image of mouse injected with unpurified
[Lys
40(
68Ga-DOTA)]exendin-3. Although high uptake in the liver is
seen, the tumour is still clearly visible
Fig. 9 Maximum intensity projection of a PET/CT image of a BALB/
c nude mouse with a subcutaneous INS-1 tumour in the right hind
limb after injection of 3 MBq HPLC-purified [Lys
40(
68Ga-DOTA)]
exendin-3. The tumour (arrow) and kidneys are clearly visible. Due to
the low background activity, the additional anatomical information
given by the CT image helps to localize the tumour
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68Ga for animal imaging may be the high
energy of the emitted β
+ particles limiting the spatial
resolution of the images to 3 mm while the intrinsic
resolution of the scanner is 1.5 mm [21]. This is only a
relevant issue in preclinical scanners, as in clinical scanners
the intrinsic resolution of the scanner rather than the β
+
energy will limit the resolution of the images.
Biodistribution studies in BALB/c nude mice with
subcutaneous INS-1 tumours showed high and specific
uptake of [Lys
40(
68Ga-DOTA)]exendin-3 in the tumour and
pancreas. Subcutaneous INS-1 tumours in the hind limb of
BALB/c nude mice were clearly visualized by microPET
imaging. Therefore, our data show that imaging of
insulinomas with
68Ga-labelled exendin is feasible.
[Lys
40(
111In-DTPA)]exendin-3 was used as a reference in
all experiments. Biodistribution studies with [Lys
40(
111In-
DTPA)]exendin-3 showed specific uptake in GLP-1R-
expressing tissues as described previously [13]. The peptide
dose escalation study revealed that in this murine model a
peptide dose of≤0.1 µg results in maximum accumulation of
radiolabelled exendin in the tumour and in GLP-1R positive
organs. Apparently, at higher doses in vivo receptors
saturation occurs. The biodistribution of [Lys
40(
111In-
DTPA)]exendin-3 was identical to the biodistribution of
[Lys
40(
111In-DTPA)]exendin-4. Also there was no measur-
able effect of the chelator on receptor targeting as the
biodistributions of [Lys
40(
111In-DTPA)]exendin-3 and
[Lys
40(DOTA)]exendin-3 were identical.
The uptake of [Lys
40(
68Ga-DOTA)]exendin-3 in the
tumour and the pancreas was significantly lower than that
of [Lys
40(
111In-DTPA)]exendin-3. It has been demonstrated
that the affinity of a peptide can be influenced by the
chelator as well as by the radionuclide. Reubi et al. showed
that
68Ga-DOTA-TATE has a higher affinity for the
somatostatin receptor subtype 2 than
111In-DOTA-TATE
[22]. However, there was no significant difference between
the IC50 values of Lys
40(
natIn-DTPA)]exendin-3, [Lys
40
(
natIn-DOTA)]exendin-3 and [Lys
40(
natGa-DOTA)]exendin-
3. The differences in tumour and pancreatic uptake between
[Lys
40(
68Ga-DOTA)]exendin-3 and [Lys
40(
111In-DTPA)]
exendin-3 could not be attributed to the substitution of
DTPA by DOTA, because in our mouse model, the uptakes
of [Lys
40(
111In-DTPA)]exendin-3 and [Lys
40(DOTA)]exen-
din-3 in the tumour and other receptor-positive organs were
identical.
Enhanced uptake of [Lys
40(
68Ga-DOTA)]exendin-3 was
seen in the liver and spleen when the preparation was only
purified by gel filtration, probably because this preparation
still contained some colloidal
68Ga. Colloidal
68Ga will
accumulate in the liver and spleen. RP-HPLC purification
removed the colloidal contamination, since this preparation
had the same very low uptake in the liver and spleen as the
111In-labelled preparation. Previous studies with
68Ga-
labelled DOTA-conjugated compounds not purified by
RP-HPLC have also shown enhanced liver and spleen
uptake [23, 24]. It is still a matter of debate whether the
enhanced uptake in liver and spleen is caused by colloidal
68Ga or by instability of the
68Ga-DOTA complex. In the
present study, uptakes of HPLC-purified [Lys
40(
68Ga-
DOTA)]exendin-3 in the liver and spleen were identical to
that of
111In-labelled exendin-3. Our data suggest that the
enhanced uptake in the liver and spleen of
68Ga-labelled
compounds found in previous studies is not caused by
instability of the
68Ga-DOTA complex but by minor
amounts of colloid.
To obtain high-quality PET images a
68Ga activity of
3 MBq was required. This necessitated the administration
of an exendin dose of 0.3 µg, and although this resulted in
suboptimal uptake (as demonstrated in the peptide dose
escalation study), the tumours could exactly be visualized.
GLP-1R is also expressed on native pancreatic beta-
cells. Radiolabelled exendin can potentially be used to
target beta-cells. This is an attractive approach for the
determination of beta-cell mass, a key issue in diabetes
mellitus. [Lys
40(
111In-DTPA)]exendin and [Lys
40(
68Ga-
DOTA)]exendin potentially can be used to noninvasively
determine the beta-cell mass in the pancreas by SPECT or
PET. A previous study has shown a correlation between the
uptake of
111In-labelled exendin and the beta-cell mass
[25], which makes this approach promising for the in vivo
determination of the beta-cell mass.
In conclusion,
68Ga-labelled [Lys
40(DOTA)]exendin-3 is
a suitable tracer for PET imaging of GLP-1R-expressing
insulinomas.
68Ga-labelled [Lys
40(DOTA)]exendin-3
showed high uptake in subcutaneous INS tumours in
BALB/c mice. Subcutaneous INS-1 tumours were clearly
visualized with a microPET/CT scanner after injection of
68Ga-labelled [Lys
40(DOTA)]exendin-3. Therefore, clinical
studies should be conducted to elucidate the potential of
[Lys
40(
68Ga-DOTA)]exendin-3 for insulinoma imaging in
humans.
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